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Introduction 
Stroke is the second leading cause of death and disability worldwide and the burden 
of stroke over the last three decades has increased significantly.1 There have also been  
noticeable changes in stroke epidemiology, including diverging trends in stroke incidence 
and mortality rates in high-income and low to middle-income countries,2 disproportionally 
increasing burden of stroke in developing countries,3 and increased proportion of disability 
and deaths due to stroke compared to all diseases.4 Moreover, while most countries have 
no accurate data on stroke incidence and outcomes,5 in countries where such studies have 
been conducted we know that there are large within and between country geographical 
differences in stroke burden,1,3 large ethnic/racial disparities in stroke,6-11 and noticeable 
secular changes in the natural history of stroke and risk factors.12,13  
All these changes, differences, trends and gaps in knowledge necessitate further, 
more advanced epidemiological studies of stroke in various populations.  Accurate and 
comparable population-based data on stroke incidence and outcomes and their trends can 
provide reliable data for evidence-based stroke care planning, health care resource 
allocation and priority setting. Current criteria for population-based stroke incidence studies 
include a standard clinical WHO definition of stroke and transient ischemic attack (TIA)14  
and maximally complete case ascertainment of both fatal and non-fatal, hospitalised and 
non-hospitalised new stroke events using multiple overlapping sources of information.15-20  
More recently, the definitions of TIA and stroke have been updated to incorporate 
both clinical and tissue criteria by the American Heart Association and American Stroke 
Association,21 and a similar definition also appears in the upcoming International 
Classification of Diseases 11th revision (ICD-11).22  The new definitions of stroke and TIA 
require a reconsideration of the criteria for an ‘ideal’ stroke incidence study. Moreover, 
there are more countries using/adapting alternative methods for population-based stroke 
incidence and outcome estimates, including national health record-linkage systems and 
various stroke registries. The issue becomes even more imperative given ongoing advances 
in acute stroke management and rehabilitation that require additional accurate 
epidemiological and health care information from stroke incidence studies. The aims of this 
article are to extend and refine the latest criteria for an ‘ideal’ stroke incidence study17,18,23 
taking into consideration the new stroke and TIA definitions and latest developments in 
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stroke care and systems with the goal of suggesting updated criteria for standard 
definitions, methods and data presentation (Table 1).  
 
Updated standard definitions of TIA and Stroke 
The addition of the WHO clinical definition of TIA (any acute focal cerebrovascular 
event with symptoms lasting <24 hours)14 to the core criteria would allow evaluation of the 
burden of two major acute cerebrovascular disorders - stroke and TIA - separately and 
combined. A wide use of thrombolytic therapy within the first hours after acute ischemic 
cerebrovascular event occurrence when the time-based clinical differentiation of stroke and 
TIA is not possible, means that new TIA events could and should be registered along with 
new stroke events. From a public health perspective, it is important to know the incidence 
of all acute cerebrovascular events, including TIA, as they all require urgent diagnosis and 
management with associated health care resource utilisation. This means that a search for 
new TIA events must be as complete and thorough as it is for new stroke events, although it 
will require additional resources and may be a challenging task in resource-poor countries. 
Additionally, adjudication of potential TIA events in a community setting is particularly 
challenging because of TIA mimics and hospitalisation bias.24,25 However, there are already a 
few population-based studies in which both stroke and TIA were ascertained and registered 
at the same time in the same study population,26-31 thus providing support for the feasibility 
of such joint stroke and TIA incidence studies in different populations.  
While it is crucial to keep using the previous WHO clinical definition of stroke 
(“rapidly developing clinical signs of focal [or global] disturbance of cerebral function, lasting 
more than 24 hours or leading to death, with no apparent cause other than that of vascular 
origin”)14 and TIA (a sudden onset of a focal neurologic symptom and/or sign lasting less 
than 24 hours and caused by reversible cerebral ischemia)14 in all epidemiological studies of 
stroke incidence to allow comparisons between different locations and over time 
(geographical and trends analysis), it is also important to include/add the new tissue-based 
definition of stroke and TIA in the latest epidemiological studies. Routine use of modern 
neuroimaging, vascular/cardiac and other laboratory investigations has become generally 
available in many hospitals/centres, thus allowing more precise etiologic and anatomical 
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classifications of TIA, ischemic stroke, intracerebral hemorrhage and subarachnoid 
hemorrhage.  
In the new AHA/ASA definition, ischemic stroke is defined on the basis of clinical and 
tissue criteria “as brain, spinal cord, or retinal cell death attributable to ischemia, based on 
neuropathological, neuroimaging, and/or clinical evidence of permanent injury”.32 
Effectively, it includes formerly defined TIAs with neuroimaging evidence of ischemic brain 
lesion in the clinically relevant area of the brain and does not depend on the duration of 
neurological symptoms associated with the cerebrovascular ischemic event. TIA is now 
defined as “transient episode of neurological dysfunction caused by focal brain, spinal cord, 
or retinal ischemia, without acute infarction”,21 thereby eliminating the time-based 
components noted in the classical WHO definition.14 Moreover, the new AHA/ASA definition 
for stroke included “silent” or “subclinical” tissue-based strokes that can only be detected 
with more sensitive brain imaging.  Most population-based incidence studies would not be 
able to adequately enumerate silent strokes because of the need for advanced imaging and 
the inability to accurately determine the date of onset of such events.  
In the upcoming ICD 11 at WHO [https://icd.who.int/dev11/l-m/en], TIA is defined as 
“Transient episode of focal neurological dysfunction caused by focal brain ischemia without 
acute infarction in the clinically relevant area of the brain. Symptoms should resolve 
completely within 24 hours”. Cerebral ischemic stroke is defined as “Acute focal 
neurological dysfunction caused by focal infarction at single or multiple sites of the brain. 
Evidence of acute infarction may come either from a) symptom duration lasting more than 
24 hours, or b) neuroimaging or other technique in the clinically relevant area of the brain. 
The term does not include infarction of the retina”. Although the ICD 11 definitions of stroke 
and TIA do not include monocular blindness with transient ischemia of the retina or retinal 
infarct, to be consistent with previous epidemiological studies of stroke we recommend to 
register these retinal ischemic events. The WHO ICD 11 definition of stroke requires the 
presence of acute neurological dysfunction and encompasses the entities cerebral ischemic 
stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and stroke not known to be 
ischemic or hemorrhagic. In the WHO ICD 11 definition, silent cerebral infarcts and 
microinfarcts are not included in the definition of stroke.  
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Both new definitions require more advanced neuroimaging or neuropathological 
confirmation of infarction.  Computerized tomography is less sensitive to detection of small 
ischemic lesions than MRI with diffusion-weighted sequences (DW-MRI), which is more 
likely to detect an acute lesion in the clinically relevant area. Increasing use of DW-MRI will 
lead to transient cerebral events labelled as TIAs under the classical WHO definition being 
called cerebral ischemic strokes under the WHO ICD-11 definition. 
According to the AHA/ASA stroke definitions, intracerebral hemorrhage is defined as 
“rapidly developing clinical signs of neurological dysfunction attributable to a focal 
collection of blood within the brain parenchyma or ventricular system that is not caused by 
trauma”; and subarachnoid hemorrhage as “rapid signs of neurological dysfunction and/or 
headache because of bleeding into the subarachnoid space (the space between the 
arachnoid membrane and pia mater of the brain or spinal cord), which is not caused by 
trauma”. These definitions of intracerebral hemorrhage and subarachnoid hemorrhage are 
similar to the ICD-11 definitions.22  
To allow meaningful comparison of epidemiological studies by stroke etiological and 
anatomical subtypes and over time it is important to use standard and validated 
classification systems. Ischemic stroke can be further classified into five etiological groups 
(large-artery atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other 
determined aetiology, and stroke of undetermined etiology) according to the Trial of Org 
10172 in Acute Stroke Treatment (TOAST) classification.33 If possible, stroke of 
undetermined etiology  can be further classified based on the extent of the diagnostic 
investigations into three groups: (1) Two or more causes identified, (2) Negative evaluation 
despite a complete investigation, and (3) Incomplete diagnostic evaluation.33  The ICD 11 
classification of cerebral ischemic stroke builds on the TOAST classification. Some studies 
have also proposed classifying a proportion of the infarcts of undetermined etiology 
(cryptogenic strokes) with adequate diagnostic investigations as embolic stroke of 
undetermined source (ESUS) among those with non-lacunar syndromes without significant 
proximal arterial atherosclerosis or a definite cardioembolic source.34 35 More recent 
etiological classification schemes, such as the Clinical Classification System, have been 
developed with the aim of providing improvements in inter-observer reliability and reducing 
the proportion of ischemic strokes attributed to undetermined etiology.36,37 Clinical 
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anatomic subgroups have also been used to classify ischemic strokes into five anatomical 
groups (total anterior circulation syndrome [TACS], partial anterior circulation syndrome 
[PACS], lacunar syndrome [LACS], posterior circulation syndrome [POCS], and uncertain 
circulation syndrome) according to the Oxfordshire Community Stroke Project [OCSP] 
clinical classification.38  This classification system provides less information on presumed 
etiology, but is less dependent on the availability of data from brain and vascular imaging, 
giving it the advantage that almost all strokes can be assigned to a subtype. Better 
comparability of studies by stroke severity are achieved through use of a well validated and 
widely used scales, such as the National Institutes of Health Stroke Scale (NIHSS).39 NIHSS 
score can be obtained either prospectively (if clearly present in medical files) or 
retrospectively based on clinical data obtained from medical files.40 Such subtype 
classification and severity scoring systems are recommended to be used as supplementary 
criteria for an ‘ideal’ stroke incidence and outcomes study.  
Although categorisation of different pathological types of stroke into various 
etiological and anatomical groups might be very challenging in population-based 
epidemiological studies, especially in resource-poor countries, there have been several such 
studies accomplished in the past.41-50 For example, if possible, intracerebral hemorrhages 
should be classified into lobar, deep, and infratentorial hemorrhages; while subarachnoid 
hemorrhages should be classified into aneurysmal and non-aneurysmal hemorrhages. These 
classifications help in the management, and predicting prognosis and planning secondary 
preventive measures, justifying their use in population-based stroke incidence studies. Such 
classification systems may also require the use of an adjudication committee to reduce bias 
and help minimize misclassification.24   
 
Suggested supplementary data collection 
Suggested additional supplementary data collection also includes registration of 
recurrent TIA (because recurrent TIA has different management and prognostic 
significance); capture-recapture estimates to ascertain the completeness of stroke and TIA 
case ascertainment,51,52 follow-up of stroke and TIA patients’ functional status for at least 3 
months (there is evidence that 3-month disability, as measured by the modified Rankin 
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Scale pre- and post-stroke, is a strong independent predictor of long-term disability and 
mortality);53,54 and collecting data on risk factors among stroke and TIA patients to allow 
firmer conclusions to be drawn about the factors impacting the trends in incidence and 
outcomes as well as to reflect on the effect of trends in health policy on stroke and TIA 
outcomes.41,55 Complete, population-based case ascertainment, based on multiple 
overlapping sources of information (hospitals, outpatient clinics, general practitioners, 
death certificates) and high level of acute brain neuroimaging coverage, with an expert 
adjudication of the events is very important for the capture and diagnosis/classification of 
all new stroke and TIA cases24 based on both old (clinical) and new stroke and TIA 
definitions. The new definitions of stroke and TIA require the use of DW-MRI for the precise 
distinction between TIA and ischemic stroke if the events are shorter than 24 hours, 
whereas for events lasting 24+ hours brain CT scanning is sufficient. Consistent with 
previous criteria for a population-based stroke incidence study,16-18 we recommend that 
when DW-MRI is done for cerebrovascular events lasting less that 24 hours it must be done 
in less than a week at least 80% of the time. Reporting of proportions examined and timing 
of the examination with each technique is important for comparative purposes. 
Given the prognostic importance of stroke for the subsequent development of 
cognitive decline and dementia, as well as its effect on quality of life and other health 
outcomes, it is also recommended to include additional validated measurements (e.g. 
cognitive impairment, daily activities, quality of life, mood, socio-economic status, direct 
and indirect costs). Preferences should be given to the validated assessment tools that are 
easier (e.g. over the phone) and faster to administer in stroke/TIA patients and their family 
caregivers. As quality and timing of acute stroke/TIA care are important determinants of 
their outcomes, it is also desirable to include some quality indicators of stroke care.56 The 
choice and number of assessment tools to be used in a population-based stroke incidence 
study should be determined by the purpose of the study, expertise of study researchers and 
available resources. 
 
Updated Standard Methods of Case Ascertainment 
The standard methods for conducting population-based stroke incidence studies are 
also applicable for determining stroke incidence using either the WHO STEPS approach to 
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stroke surveillance,19 national registries (e.g. record-linkage systems) or a special door-to-
door survey20 (Figure).  These survey methods require use of instruments that allow clinical 
ascertainment of non-hospitalized and non-fatal stroke and TIA events among study 
participants and include a validated verbal-autopsy technique for fatal events (interviewing 
family members and/or relevant health professionals about the circumstances of a death of 
after the event over the last couple of years). Such door-to-door surveys for studying stroke 
incidence have been successfully accomplished in Italy and China.57-59 Advantages of this 
approach include relatively low cost and simplicity (door-to-door survey is the most 
commonly used design of stroke epidemiological studies in resource-poor settings). 
Disadvantages include the potential for under-estimating incidence rates by missing very 
mild stroke cases, recall bias (although this can be minimized by restricting the period of 
recall to 3 years), and the need to study a large sample size.20 It should be emphasised that 
the WHO STEPS stroke surveillance can only be called a population-based study if it includes 
all three steps of the surveillance (hospital register, death certificates and non-hospitalised 
case ascertainment in the catchment area).  The updated classifications of TIA and stroke 
may also require greater access to advanced brain imaging to use classification systems that 
rely on tissue-based criteria for infarction and hemorrhage.  
 
Updated standard data presentation 
To allow comparisons between different stroke incidence studies and analysis of 
temporal trends, it is important to conduct a study in a way that (a) allows accommodation 
of both core and supplementary criteria, and (b) follows standard guidelines for reporting 
study results, such as the Standards of Reporting of Neurological Disorders Checklist 
(STROND)(Table 2).60,61 We suggest calling a study that meets both core and supplementary 
criteria and standard data presentation (Tables 1 and 2) an ‘advanced’ population-based 
stroke incidence study. However, such stroke incidence studies are expensive and require 
special expertise for their design and execution, which is particularly challenging in 
resource-poor countries. Therefore, studies that meet just basic criteria for a stroke 
incidence study set up by Malmgren et al.15 and then updated by Sudlow and Warlow16 
(including studies that accommodate all three WHO STEPS surveys and studies based on a 
special door-to-door survey, as explained above) remain acceptable as basic population-
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based stroke and/or TIA incidence studies. There is an obvious lack of even these studies in 
most parts of the world,5,27 and even fewer population-based stroke incidence studies exist 
on trends in stroke incidence and outcomes.  
For stroke incidence studies that use the new definitions of stroke, data on TIA with 
or without neuroimaging evidence of brain infarct, data on stroke and TIA by age, sex 
and/or ethnic/racial groups should be presented separately and combined. A checklist for 
standard data reporting is presented in Table 2. 
 
Impact and implication of new criteria 
As suggested by Sacco et al.62 changing the definition of stroke and TIA will have 
significant effects on stroke/TIA surveillance, burden estimates and prognosis. As the new 
clinical and tissue-based stroke definition will include formerly diagnosed TIAs with evidence 
of brain lesion, the number of strokes will be increased, and overall stroke severity reduced. 
Preliminary estimates suggest that adopting this definition of stroke, for example, in the 
USA would lower annual incidence rates of TIA by 33%, but increase the rate of ischemic 
stroke by 33%.11,63 It is likely that overall stroke severity will also be reduced by 
approximately the same amount. However, population-based studies in various populations 
adopting the new definitions of stroke and TIA are required to estimate the effect of 
changing stroke and TIA definitions on stroke and TIA incidence and outcomes and to 
provide new comparable estimates. It is our hope that the wider use of the updated 
alongside the classical criteria for population-based stroke incidence studies will advance 
our knowledge on changing stroke epidemiology in the world and further facilitate 
evidence-based health care planning, priority setting, and resource allocation for people 
with acute cerebrovascular events, and, as consequence, save millions of lives. 
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Table 1. Criteria for basic and advanced population-based stroke and TIA incidence studies 
(Adapted from Feigin et al.,17,18  with permission) 
 
Domains Core criteria for Basic Studies  Supplementary criteria for Advanced Studies  
Standard 
definitions 
WHO clinical definition of stroke 
WHO clinical definition of TIA* 
At least 80% CT/MRI verification of the 
diagnosis of ischemic stroke, intracerebral 
hemorrhage, and subarachnoid 
hemorrhage within first week of stroke 
onset 
First ever-in-a-lifetime stroke or TIA 
AHA/ASA/ICD-11 clinical and tissue definition of stroke* 
TIA without evidence of brain infarct* 
At least 80% DW-MRI for tissue-based distinction of TIA 
and stroke for events resolving within first 24 hours of 
the onset* 
Classification of ischemic stroke, intracerebral 
hemorrhage and subarachnoid hemorrhage into 
etiological and anatomical groups*  
Stroke severity by NIHSS or similar* 
Recurrent stroke and TIA* 
Standard 
methods 
Complete, population-based case 
ascertainment, based on multiple 
overlapping sources of information 
(hospitals, outpatient clinics, general 
practitioners, death certificates) 
Prospective study design 
Large, well-defined, and stable 
population, allowing at least 100,000 
person-years of observation 
 
Reliable method for estimating 
denominator (census data 5 years old) 
Follow-up of patients’ vital status for at 
least 1 month 
Ascertainment of patients with TIA, recurrent strokes 
and those referred for brain, carotid, or cerebral 
vascular imaging 
 
“Hot pursuit’ of cases 
Direct assessment of under-ascertainment by regular 
checking of general practitioners’ databases and 
hospital admissions for acute vascular problems and 
cerebrovascular imaging studies and/or interventions 
Capture-recapture estimates of the completeness of 
case ascertainment* 
Follow-up of stroke and TIA patients’ functional status 
for at least 3 months* 
Collecting data on stroke risk factors and quality of 
acute care* 
Standard 
data 
presentation 
Complete calendar years of data; 5 years 
of data averaged together 
Men and women presented separately 
Mid-decade 10 or 5-year age bands (e.g. 
55 to 64 years) used in publications, 
including oldest age group (85 years) 
Data on old (WHO) and new (AHA/ASA/ICD-11) stroke 
and TIA estimates presented separately* 
Data also presented by major ethnic/racial groups* 
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95% confidence interval around rates 
STROND guidelines for reporting* 
*New criteria. 
 
Table 2. Standards for reporting population-based stroke and TIA incidence studies 
(Adapted from Bennett et al.,60 with permission) 
 
SECTION/TOPIC RECOMMENDATION 
Title  Give the type of study design employed using a widely recognised term 
Abstract The abstract should give an accurate summary of how the study was conducted and the 
main findings 
Introduction 
   Background 
   Aims/objectives 
 
Details of the scientific rationale for the study should be reported 
State the specific aims and objectives of the study 
Methods 
    Study design 
 
   Setting 
 
   Source population 
 
 
 
 
 
 
   Study participants 
 
 
 
 
 
   Ethical approval 
   Measurement 
 
 
 
   Statistical methods 
 
Give a full description of the study design, and what criteria it meets to be called a 
population-based study 
Clearly defined (usually, but not always, on a geographic basis), and stable, with reliable 
information on in- and out-migration 
Description of how all eligible members of the population were identified and through 
what data sources (e.g. hospitals, outpatient clinics, death certificates). Source of data 
used for the study (e.g. administrative database, medical records). If administrative 
database used algorithms for data extraction should be described. Description of the rate 
of hospital admission. Details of health care system in the country (study region) where 
the study was conducted (e.g. public versus private health care system). Description of 
how a person with stroke or TIA is referred in the country (study region) where the study 
was conducted. Description and characteristics of response rate/drop outs and exclusion 
rate if applicable. 
Definition of stroke and/or TIA is clearly identified and presented in sufficient detail. 
Details of the sampling method are described (are participants representative of the 
source population). Fully validated source of diagnosis or ‘‘reference-standard’’ criteria 
applied. Definition and justification of disease severity (preferably using a standardised 
scale). Description of how types/subtypes of stroke/TIA are distinguished (if relevant). 
Description of how completeness of case-ascertainment was assessed. Description of 
whether completeness of case ascertainment was adequate. 
Details of ethics approval/informed consent/data governance should be reported. 
Give details of how incidence was determined (based on timing of data collection either 
prospectively or retrospectively). Definition and justification of timing of measurements. 
The data presented to some specified time period (usually whole years or person-time). 
Raw numbers are reported in sufficient detail to calculate the appropriate rates (e.g. by 
age or gender). 
If rates have been standardised (e.g. by age or gender), then the details of the standard 
population used should be given. If possible two standard populations should be used 
one with local relevance and the other to facilitate international comparisons. 
Description of any assumptions made in the calculations should be reported. An 
explanation of how missing data was addressed in the analyses. 
Results 
   Main findings 
 
Consider a flow diagram that describes how participants were included in the study 
(useful in order to assess how a person with stroke/TIA is referred). Give appropriate 
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rates with their associated 95% confidence intervals. Report results of any sensitivity 
analyses. 
Discussion 
   Key findings 
   Interpretation 
 
    
 
   Limitations 
    
  Generalisability 
 
   Implications 
 
Summarise the key findings in relation to the study aims and objectives.  
Interpret the results in the context of the evidence from other well performed studies 
with similar designs and objectives. Reliability of the estimates (i.e. based on the 
reporting of the statistical methodology, and study design, measurement of key 
information) 
Discuss potential limitations of the study. Include details of risk of bias (e.g. selection 
bias), completeness of case ascertainment, and data quality (assessment of its 
probability, size and potential importance) 
Discuss the external validity of the study findings. Are the results consistent with reviews 
of descriptive epidemiological studies on the same topic that cover different settings. 
Discuss implications of the research findings for practice and future research 
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Figure. A basic population-based stroke and TIA incidence study utilising door-to-door 
survey (Adapted from Feigin,20 with permission) 
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